ArticleJournal of inflammation research2024
The Diagnostic Value of Systemic Immune-Inflammatory Index (SII) and Lymphocyte-Albumin-Neutrophil Ratio (LANR) in Chronic Obstructive Pulmonary Disease with Lung Cancer.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- From Alveolar Injury to Precision Perioperative Care: Integrating Molecular Biomarkers and Technology-Enabled Strategies for Prolonged Air Leak After Lung Resection.Mediators of inflammation · 2026Review
- The impact of inflammation on the incidence of different pathological types of lung cancer: the Kailuan study.Frontiers in oncology · 2026Article
- Integrating Machine Learning for Early COPD Prediction in Lung Cancer Patients: A Focus on Systemic Coagulation-Inflammation Index.International journal of chronic obstructive pulmonary disease · 2026Article
- The correlation between systemic inflammatory index and rebleeding after bronchial artery embolization: a retrospective cohort study.International journal of emergency medicine · 2025Article
- Article
- Evaluating the Inflammatory Protein Ratio (IPR) as an Inflammation-Based Biomarker for Cancer Diagnosis.International journal of molecular sciences · 2025Article
- Neutrophil-to-lymphocyte ratio as a prognostic marker for lung cancer in combined pulmonary fibrosis and emphysema patients.European journal of medical research · 2025Article
- Perioperative inflammatory index differences between pulmonary squamous cell carcinoma and adenocarcinoma and their prognostic implications.Frontiers in oncology · 2025Article
- Association between systemic immune-inflammation index and mortality in critically ill patients with chronic obstructive pulmonary disease: insights from the MIMIC-IV database.Frontiers in medicine · 2025Article
- Association between immuno-nutritional biomarkers and mortality in hospitalized geriatric population.Frontiers in immunology · 2025Observational
- Difference in the ratio of low-density lipoprotein to lymphocytes between acute exacerbation of and stable phase of chronic obstructive pulmonary disease patients.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to explore the association of inflammatory markers such as the Systemic Immune-Inflammatory Index (SII) and LANR with the comorbidity of Chronic Obstructive Pulmonary Disease (COPD) and lung cancer. Patients and Methods: A cross-sectional analysis was conducted on the clinical data of 309 patients with COPD only and 193 patients with COPD and lung cancer who attended the First Affiliated Hospital of Anhui Medical University. Additionally, we examined autonomous risk factors that contribute to the simultaneous development of COPD and lung cancer through univariate and multivariate logistic regression analyses. This analysis resulted in the development of a nomogram model for visual representation. The effectiveness of the model was assessed using a receiver operating characteristic (ROC) curve, calibration curve, and clinical decision analysis (DCA) curve, with internal validation conducted via repeated sampling methods. Results: Multivariate analysis of clinical characteristics and inflammatory markers showed that smoking history of >60 pack-years, hemoptysis, emphysema, WBC count > 5.53 (×10^9/L), SII > 629.285, and LANR < 11.39 were significantly associated with the comorbidity of COPD and lung cancer. These factors were subsequently integrated into the nomogram model. The AUC of the model stood at 0.849 (95% CI: 0.815-0.882), demonstrating a notable improvement over the COPD-LUCSS scoring system (AUC: 0.716, 95% CI: 0.671-0.761). The DCA curve indicated a notable clinical advantage provided by the model. Additionally, patients with stage IV tumors exhibited elevated SII levels and reduced LANR levels compared to earlier stages, indicating potential prognostic significance for both markers. Conclusion: Increased levels of the inflammatory markers SII and LANR are associated with the risk of comorbidity of COPD and lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.